img

Global Long-acting Beta Agonists Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Long-acting Beta Agonists Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Long-Acting Beta Agonists (LABAs) are inhaled medications that are used in the treatment of asthma and chronic obstuctive pulmonary disease (COPD).
Long-acting Beta Agonists report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Long-acting Beta Agonists market is projected to reach US$ 5479.6 million in 2029, increasing from US$ 4152 million in 2022, with the CAGR of 3.2% during the period of 2024 to 2029. Demand from COPD and Asthma are the major drivers for the industry.
The inhalation combination product market is driven by the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) and the demand for more effective and convenient treatment options. Inhalation combination products offer a combination of two or more medications in a single device, providing patients with better disease management and improved treatment adherence. These products offer advantages such as simplified dosing regimens, enhanced efficacy, and reduced side effects compared to multiple separate inhalers. Additionally, advancements in inhalation technology, such as metered-dose inhalers and dry powder inhalers, have further fueled the adoption of combination products. However, the market also faces challenges, including the complexity of formulation development and the need for rigorous testing to ensure compatibility and stability of the combined medications. Moreover, regulatory requirements for combination products can be more stringent than individual drugs, making the approval process more challenging. To succeed in this market, manufacturers must invest in research and development to optimize combination therapies, address regulatory concerns, and educate healthcare professionals and patients about the benefits of inhalation combination products.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Long-acting Beta Agonists market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


GSK
AstraZeneca
Chiesi
Boehringer Ingelheim
Novartis
Teva
Organon
Segment by Type
Serevent
Foradil
Striverdi
Other

Segment by Application


COPD
Asthma
Other

Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Long-acting Beta Agonists market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Long-acting Beta Agonists, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Long-acting Beta Agonists industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Long-acting Beta Agonists in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Long-acting Beta Agonists introduction, etc. Long-acting Beta Agonists Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Long-acting Beta Agonists market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Long-acting Beta Agonists Market Overview
1.1 Long-acting Beta Agonists Product Overview
1.2 Long-acting Beta Agonists Market Segment by Type
1.2.1 Serevent
1.2.2 Foradil
1.2.3 Striverdi
1.2.4 Other
1.3 Global Long-acting Beta Agonists Market Size by Type
1.3.1 Global Long-acting Beta Agonists Market Size Overview by Type (2018-2029)
1.3.2 Global Long-acting Beta Agonists Historic Market Size Review by Type (2018-2024)
1.3.3 Global Long-acting Beta Agonists Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Long-acting Beta Agonists Sales Breakdown by Type (2018-2024)
1.4.2 Europe Long-acting Beta Agonists Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Long-acting Beta Agonists Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Long-acting Beta Agonists Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Long-acting Beta Agonists Sales Breakdown by Type (2018-2024)
2 Global Long-acting Beta Agonists Market Competition by Company
2.1 Global Top Players by Long-acting Beta Agonists Sales (2018-2024)
2.2 Global Top Players by Long-acting Beta Agonists Revenue (2018-2024)
2.3 Global Top Players by Long-acting Beta Agonists Price (2018-2024)
2.4 Global Top Manufacturers Long-acting Beta Agonists Manufacturing Base Distribution, Sales Area, Product Type
2.5 Long-acting Beta Agonists Market Competitive Situation and Trends
2.5.1 Long-acting Beta Agonists Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Long-acting Beta Agonists Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Long-acting Beta Agonists as of 2022)
2.7 Date of Key Manufacturers Enter into Long-acting Beta Agonists Market
2.8 Key Manufacturers Long-acting Beta Agonists Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Long-acting Beta Agonists Status and Outlook by Region
3.1 Global Long-acting Beta Agonists Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Long-acting Beta Agonists Historic Market Size by Region
3.2.1 Global Long-acting Beta Agonists Sales in Volume by Region (2018-2024)
3.2.2 Global Long-acting Beta Agonists Sales in Value by Region (2018-2024)
3.2.3 Global Long-acting Beta Agonists Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Long-acting Beta Agonists Forecasted Market Size by Region
3.3.1 Global Long-acting Beta Agonists Sales in Volume by Region (2024-2029)
3.3.2 Global Long-acting Beta Agonists Sales in Value by Region (2024-2029)
3.3.3 Global Long-acting Beta Agonists Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Long-acting Beta Agonists by Application
4.1 Long-acting Beta Agonists Market Segment by Application
4.1.1 COPD
4.1.2 Asthma
4.1.3 Other
4.2 Global Long-acting Beta Agonists Market Size by Application
4.2.1 Global Long-acting Beta Agonists Market Size Overview by Application (2018-2029)
4.2.2 Global Long-acting Beta Agonists Historic Market Size Review by Application (2018-2024)
4.2.3 Global Long-acting Beta Agonists Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Long-acting Beta Agonists Sales Breakdown by Application (2018-2024)
4.3.2 Europe Long-acting Beta Agonists Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Long-acting Beta Agonists Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Long-acting Beta Agonists Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Long-acting Beta Agonists Sales Breakdown by Application (2018-2024)
5 North America Long-acting Beta Agonists by Country
5.1 North America Long-acting Beta Agonists Historic Market Size by Country
5.1.1 North America Long-acting Beta Agonists Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Long-acting Beta Agonists Sales in Volume by Country (2018-2024)
5.1.3 North America Long-acting Beta Agonists Sales in Value by Country (2018-2024)
5.2 North America Long-acting Beta Agonists Forecasted Market Size by Country
5.2.1 North America Long-acting Beta Agonists Sales in Volume by Country (2024-2029)
5.2.2 North America Long-acting Beta Agonists Sales in Value by Country (2024-2029)
6 Europe Long-acting Beta Agonists by Country
6.1 Europe Long-acting Beta Agonists Historic Market Size by Country
6.1.1 Europe Long-acting Beta Agonists Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Long-acting Beta Agonists Sales in Volume by Country (2018-2024)
6.1.3 Europe Long-acting Beta Agonists Sales in Value by Country (2018-2024)
6.2 Europe Long-acting Beta Agonists Forecasted Market Size by Country
6.2.1 Europe Long-acting Beta Agonists Sales in Volume by Country (2024-2029)
6.2.2 Europe Long-acting Beta Agonists Sales in Value by Country (2024-2029)
7 Asia-Pacific Long-acting Beta Agonists by Region
7.1 Asia-Pacific Long-acting Beta Agonists Historic Market Size by Region
7.1.1 Asia-Pacific Long-acting Beta Agonists Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Long-acting Beta Agonists Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Long-acting Beta Agonists Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Long-acting Beta Agonists Forecasted Market Size by Region
7.2.1 Asia-Pacific Long-acting Beta Agonists Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Long-acting Beta Agonists Sales in Value by Region (2024-2029)
8 Latin America Long-acting Beta Agonists by Country
8.1 Latin America Long-acting Beta Agonists Historic Market Size by Country
8.1.1 Latin America Long-acting Beta Agonists Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Long-acting Beta Agonists Sales in Volume by Country (2018-2024)
8.1.3 Latin America Long-acting Beta Agonists Sales in Value by Country (2018-2024)
8.2 Latin America Long-acting Beta Agonists Forecasted Market Size by Country
8.2.1 Latin America Long-acting Beta Agonists Sales in Volume by Country (2024-2029)
8.2.2 Latin America Long-acting Beta Agonists Sales in Value by Country (2024-2029)
9 Middle East and Africa Long-acting Beta Agonists by Country
9.1 Middle East and Africa Long-acting Beta Agonists Historic Market Size by Country
9.1.1 Middle East and Africa Long-acting Beta Agonists Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Long-acting Beta Agonists Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Long-acting Beta Agonists Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Long-acting Beta Agonists Forecasted Market Size by Country
9.2.1 Middle East and Africa Long-acting Beta Agonists Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Long-acting Beta Agonists Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 GSK
10.1.1 GSK Company Information
10.1.2 GSK Introduction and Business Overview
10.1.3 GSK Long-acting Beta Agonists Sales, Revenue and Gross Margin (2018-2024)
10.1.4 GSK Long-acting Beta Agonists Products Offered
10.1.5 GSK Recent Development
10.2 AstraZeneca
10.2.1 AstraZeneca Company Information
10.2.2 AstraZeneca Introduction and Business Overview
10.2.3 AstraZeneca Long-acting Beta Agonists Sales, Revenue and Gross Margin (2018-2024)
10.2.4 AstraZeneca Long-acting Beta Agonists Products Offered
10.2.5 AstraZeneca Recent Development
10.3 Chiesi
10.3.1 Chiesi Company Information
10.3.2 Chiesi Introduction and Business Overview
10.3.3 Chiesi Long-acting Beta Agonists Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Chiesi Long-acting Beta Agonists Products Offered
10.3.5 Chiesi Recent Development
10.4 Boehringer Ingelheim
10.4.1 Boehringer Ingelheim Company Information
10.4.2 Boehringer Ingelheim Introduction and Business Overview
10.4.3 Boehringer Ingelheim Long-acting Beta Agonists Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Boehringer Ingelheim Long-acting Beta Agonists Products Offered
10.4.5 Boehringer Ingelheim Recent Development
10.5 Novartis
10.5.1 Novartis Company Information
10.5.2 Novartis Introduction and Business Overview
10.5.3 Novartis Long-acting Beta Agonists Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Novartis Long-acting Beta Agonists Products Offered
10.5.5 Novartis Recent Development
10.6 Teva
10.6.1 Teva Company Information
10.6.2 Teva Introduction and Business Overview
10.6.3 Teva Long-acting Beta Agonists Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Teva Long-acting Beta Agonists Products Offered
10.6.5 Teva Recent Development
10.7 Organon
10.7.1 Organon Company Information
10.7.2 Organon Introduction and Business Overview
10.7.3 Organon Long-acting Beta Agonists Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Organon Long-acting Beta Agonists Products Offered
10.7.5 Organon Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Long-acting Beta Agonists Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Long-acting Beta Agonists Industrial Chain Analysis
11.4 Long-acting Beta Agonists Market Dynamics
11.4.1 Long-acting Beta Agonists Industry Trends
11.4.2 Long-acting Beta Agonists Market Drivers
11.4.3 Long-acting Beta Agonists Market Challenges
11.4.4 Long-acting Beta Agonists Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Long-acting Beta Agonists Distributors
12.3 Long-acting Beta Agonists Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Serevent
Table 2. Major Company of Foradil
Table 3. Major Company of Striverdi
Table 4. Major Company of Other
Table 5. Global Long-acting Beta Agonists Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Long-acting Beta Agonists Sales by Type (2018-2024) & (K Units)
Table 7. Global Long-acting Beta Agonists Sales Market Share in Volume by Type (2018-2024)
Table 8. Global Long-acting Beta Agonists Sales by Type (2018-2024) & (US& Million)
Table 9. Global Long-acting Beta Agonists Market Share in Value by Type (2018-2024)
Table 10. Global Long-acting Beta Agonists Price by Type (2018-2024) & (US$/Unit)
Table 11. Global Long-acting Beta Agonists Sales by Type (2024-2029) & (K Units)
Table 12. Global Long-acting Beta Agonists Sales Market Share in Volume by Type (2024-2029)
Table 13. Global Long-acting Beta Agonists Sales by Type (2024-2029) & (US$ Million)
Table 14. Global Long-acting Beta Agonists Sales Market Share in Value by Type (2024-2029)
Table 15. Global Long-acting Beta Agonists Price by Type (2024-2029) & (US$/Unit)
Table 16. North America Long-acting Beta Agonists Sales by Type (2018-2024) & (K Units)
Table 17. North America Long-acting Beta Agonists Sales by Type (2018-2024) & (US$ Million)
Table 18. Europe Long-acting Beta Agonists Sales (K Units) by Type (2018-2024)
Table 19. Europe Long-acting Beta Agonists Sales by Type (2018-2024) & (US$ Million)
Table 20. Asia-Pacific Long-acting Beta Agonists Sales (K Units) by Type (2018-2024)
Table 21. Asia-Pacific Long-acting Beta Agonists Sales by Type (2018-2024) & (US$ Million)
Table 22. Latin America Long-acting Beta Agonists Sales (K Units) by Type (2018-2024)
Table 23. Latin America Long-acting Beta Agonists Sales by Type (2018-2024) & (US$ Million)
Table 24. Middle East and Africa Long-acting Beta Agonists Sales (K Units) by Type (2018-2024)
Table 25. Middle East and Africa Long-acting Beta Agonists Sales by Type (2018-2024) & (US$ Million)
Table 26. Global Long-acting Beta Agonists Sales by Company (2018-2024) & (K Units)
Table 27. Global Long-acting Beta Agonists Sales Share by Company (2018-2024)
Table 28. Global Long-acting Beta Agonists Revenue by Company (2018-2024) & (US$ Million)
Table 29. Global Long-acting Beta Agonists Revenue Share by Company (2018-2024)
Table 30. Global Market Long-acting Beta Agonists Price by Company (2018-2024) & (US$/Unit)
Table 31. Global Long-acting Beta Agonists Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 32. Global Long-acting Beta Agonists Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 33. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Long-acting Beta Agonists as of 2022)
Table 34. Date of Key Manufacturers Enter into Long-acting Beta Agonists Market
Table 35. Key Manufacturers Long-acting Beta Agonists Product Type
Table 36. Mergers & Acquisitions, Expansion Plans
Table 37. Global Long-acting Beta Agonists Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Global Long-acting Beta Agonists Sales by Region (2018-2024) & (K Units)
Table 39. Global Long-acting Beta Agonists Sales Market Share in Volume by Region (2018-2024)
Table 40. Global Long-acting Beta Agonists Sales by Region (2018-2024) & (US$ Million)
Table 41. Global Long-acting Beta Agonists Sales Market Share in Value by Region (2018-2024)
Table 42. Global Long-acting Beta Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 43. Global Long-acting Beta Agonists Sales by Region (2024-2029) & (K Units)
Table 44. Global Long-acting Beta Agonists Sales Market Share in Volume by Region (2024-2029)
Table 45. Global Long-acting Beta Agonists Sales by Region (2024-2029) & (US$ Million)
Table 46. Global Long-acting Beta Agonists Sales Market Share in Value by Region (2024-2029)
Table 47. Global Long-acting Beta Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2029)
Table 48. Global Long-acting Beta Agonists Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 49. Global Long-acting Beta Agonists Sales by Application (2018-2024) & (K Units)
Table 50. Global Long-acting Beta Agonists Sales Market Share in Volume by Application (2018-2024)
Table 51. Global Long-acting Beta Agonists Sales by Application (2018-2024) & (US$ Million)
Table 52. Global Long-acting Beta Agonists Sales Market Share in Value by Application (2018-2024)
Table 53. Global Long-acting Beta Agonists Price by Application (2018-2024) & (US$/Unit)
Table 54. Global Long-acting Beta Agonists Sales by Application (2024-2029) & (K Units)
Table 55. Global Long-acting Beta Agonists Sales Market Share in Volume by Application (2024-2029)
Table 56. Global Long-acting Beta Agonists Sales by Application (2024-2029) & (US$ Million)
Table 57. Global Long-acting Beta Agonists Sales Market Share in Value by Application (2024-2029)
Table 58. Global Long-acting Beta Agonists Price by Application (2024-2029) & (US$/Unit)
Table 59. North America Long-acting Beta Agonists Sales by Application (2018-2024) (K Units)
Table 60. North America Long-acting Beta Agonists Sales by Application (2018-2024) & (US$ Million)
Table 61. Europe Long-acting Beta Agonists Sales by Application (2018-2024) (K Units)
Table 62. Europe Long-acting Beta Agonists Sales by Application (2018-2024) & (US$ Million)
Table 63. Asia-Pacific Long-acting Beta Agonists Sales by Application (2018-2024) (K Units)
Table 64. Asia-Pacific Long-acting Beta Agonists Sales by Application (2018-2024) & (US$ Million)
Table 65. Latin America Long-acting Beta Agonists Sales by Application (2018-2024) (K Units)
Table 66. Latin America Long-acting Beta Agonists Sales by Application (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Long-acting Beta Agonists Sales by Application (2018-2024) (K Units)
Table 68. Middle East and Africa Long-acting Beta Agonists Sales by Application (2018-2024) & (US$ Million)
Table 69. North America Long-acting Beta Agonists Sales by Country (2018-2024) & (K Units)
Table 70. North America Long-acting Beta Agonists Sales Market Share in Volume by Country (2018-2024)
Table 71. North America Long-acting Beta Agonists Sales by Country (2018-2024) & (US$ Million)
Table 72. North America Long-acting Beta Agonists Sales Market Share in Value by Country (2018-2024)
Table 73. North America Long-acting Beta Agonists Sales by Country (2024-2029) & (K Units)
Table 74. North America Long-acting Beta Agonists Sales Market Share in Volume by Country (2024-2029)
Table 75. North America Long-acting Beta Agonists Sales by Country (2024-2029) & (US$ Million)
Table 76. North America Long-acting Beta Agonists Sales Market Share in Value by Country (2024-2029)
Table 77. Europe Long-acting Beta Agonists Sales by Country (2018-2024) & (K Units)
Table 78. Europe Long-acting Beta Agonists Sales Market Share in Volume by Country (2018-2024)
Table 79. Europe Long-acting Beta Agonists Sales by Country (2018-2024) & (US$ Million)
Table 80. Europe Long-acting Beta Agonists Sales Market Share in Value by Country (2018-2024)
Table 81. Europe Long-acting Beta Agonists Sales by Country (2024-2029) & (K Units)
Table 82. Europe Long-acting Beta Agonists Sales Market Share in Volume by Country (2024-2029)
Table 83. Europe Long-acting Beta Agonists Sales by Country (2024-2029) & (US$ Million)
Table 84. Europe Long-acting Beta Agonists Sales Market Share in Value by Country (2024-2029)
Table 85. Asia-Pacific Long-acting Beta Agonists Sales by Region (2018-2024) & (K Units)
Table 86. Asia-Pacific Long-acting Beta Agonists Sales Market Share in Volume by Region (2018-2024)
Table 87. Asia-Pacific Long-acting Beta Agonists Sales by Region (2018-2024) & (US$ Million)
Table 88. Asia-Pacific Long-acting Beta Agonists Sales Market Share in Value by Region (2018-2024)
Table 89. Asia-Pacific Long-acting Beta Agonists Sales by Region (2024-2029) & (K Units)
Table 90. Asia-Pacific Long-acting Beta Agonists Sales Market Share in Volume by Region (2024-2029)
Table 91. Asia-Pacific Long-acting Beta Agonists Sales by Region (2024-2029) & (US$ Million)
Table 92. Asia-Pacific Long-acting Beta Agonists Sales Market Share in Value by Region (2024-2029)
Table 93. Latin America Long-acting Beta Agonists Sales by Country (2018-2024) & (K Units)
Table 94. Latin America Long-acting Beta Agonists Sales Market Share in Volume by Country (2018-2024)
Table 95. Latin America Long-acting Beta Agonists Sales by Country (2018-2024) & (US$ Million)
Table 96. Latin America Long-acting Beta Agonists Sales Market Share in Value by Country (2018-2024)
Table 97. Latin America Long-acting Beta Agonists Sales by Country (2024-2029) & (K Units)
Table 98. Latin America Long-acting Beta Agonists Sales Market Share in Volume by Country (2024-2029)
Table 99. Latin America Long-acting Beta Agonists Sales by Country (2024-2029) & (US$ Million)
Table 100. Latin America Long-acting Beta Agonists Sales Market Share in Value by Country (2024-2029)
Table 101. Middle East and Africa Long-acting Beta Agonists Sales by Country (2018-2024) & (K Units)
Table 102. Middle East and Africa Long-acting Beta Agonists Sales Market Share in Volume by Country (2018-2024)
Table 103. Middle East and Africa Long-acting Beta Agonists Sales by Country (2018-2024) & (US$ Million)
Table 104. Middle East and Africa Long-acting Beta Agonists Sales Market Share in Value by Country (2018-2024)
Table 105. Middle East and Africa Long-acting Beta Agonists Sales by Country (2024-2029) & (K Units)
Table 106. Middle East and Africa Long-acting Beta Agonists Sales Market Share in Volume by Country (2024-2029)
Table 107. Middle East and Africa Long-acting Beta Agonists Sales by Country (2024-2029) & (US$ Million)
Table 108. Middle East and Africa Long-acting Beta Agonists Sales Market Share in Value by Country (2024-2029)
Table 109. GSK Company Information
Table 110. GSK Introduction and Business Overview
Table 111. GSK Long-acting Beta Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 112. GSK Long-acting Beta Agonists Product
Table 113. GSK Recent Development
Table 114. AstraZeneca Company Information
Table 115. AstraZeneca Introduction and Business Overview
Table 116. AstraZeneca Long-acting Beta Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 117. AstraZeneca Long-acting Beta Agonists Product
Table 118. AstraZeneca Recent Development
Table 119. Chiesi Company Information
Table 120. Chiesi Introduction and Business Overview
Table 121. Chiesi Long-acting Beta Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 122. Chiesi Long-acting Beta Agonists Product
Table 123. Chiesi Recent Development
Table 124. Boehringer Ingelheim Company Information
Table 125. Boehringer Ingelheim Introduction and Business Overview
Table 126. Boehringer Ingelheim Long-acting Beta Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 127. Boehringer Ingelheim Long-acting Beta Agonists Product
Table 128. Boehringer Ingelheim Recent Development
Table 129. Novartis Company Information
Table 130. Novartis Introduction and Business Overview
Table 131. Novartis Long-acting Beta Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 132. Novartis Long-acting Beta Agonists Product
Table 133. Novartis Recent Development
Table 134. Teva Company Information
Table 135. Teva Introduction and Business Overview
Table 136. Teva Long-acting Beta Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 137. Teva Long-acting Beta Agonists Product
Table 138. Teva Recent Development
Table 139. Organon Company Information
Table 140. Organon Introduction and Business Overview
Table 141. Organon Long-acting Beta Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 142. Organon Long-acting Beta Agonists Product
Table 143. Organon Recent Development
Table 144. Key Raw Materials Lists
Table 145. Raw Materials Key Suppliers Lists
Table 146. Long-acting Beta Agonists Market Trends
Table 147. Long-acting Beta Agonists Market Drivers
Table 148. Long-acting Beta Agonists Market Challenges
Table 149. Long-acting Beta Agonists Market Restraints
Table 150. Long-acting Beta Agonists Distributors List
Table 151. Long-acting Beta Agonists Downstream Customers
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Long-acting Beta Agonists Product Picture
Figure 2. Global Long-acting Beta Agonists Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Long-acting Beta Agonists Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global Long-acting Beta Agonists Sales Status and Outlook (2018-2029) & (K Units)
Figure 5. Product Picture of Serevent
Figure 6. Global Serevent Sales YoY Growth (2018-2029) & (K Units)
Figure 7. Product Picture of Foradil
Figure 8. Global Foradil Sales YoY Growth (2018-2029) & (K Units)
Figure 9. Product Picture of Striverdi
Figure 10. Global Striverdi Sales YoY Growth (2018-2029) & (K Units)
Figure 11. Product Picture of Other
Figure 12. Global Other Sales YoY Growth (2018-2029) & (K Units)
Figure 13. Global Long-acting Beta Agonists Sales by Type (2018-2029) & (US$ Million)
Figure 14. Global Long-acting Beta Agonists Sales Market Share by Type in 2022 & 2029
Figure 15. North America Long-acting Beta Agonists Sales Market Share in Volume by Type in 2022
Figure 16. North America Long-acting Beta Agonists Sales Market Share in Value by Type in 2022
Figure 17. Europe Long-acting Beta Agonists Sales Market Share in Volume by Type in 2022
Figure 18. Europe Long-acting Beta Agonists Sales Market Share in Value by Type in 2022
Figure 19. Asia-Pacific Long-acting Beta Agonists Sales Market Share in Volume by Type in 2022
Figure 20. Asia-Pacific Long-acting Beta Agonists Sales Market Share in Value by Type in 2022
Figure 21. Latin America Long-acting Beta Agonists Sales Market Share in Volume by Type in 2022
Figure 22. Latin America Long-acting Beta Agonists Sales Market Share in Value by Type in 2022
Figure 23. Middle East and Africa Long-acting Beta Agonists Sales Market Share in Volume by Type in 2022
Figure 24. Middle East and Africa Long-acting Beta Agonists Sales Market Share in Value by Type in 2022
Figure 25. The 5 and 10 Largest Manufacturers in the World: Market Share by Long-acting Beta Agonists Sales in 2022
Figure 26. The 5 and 10 Largest Manufacturers in the World: Market Share by Long-acting Beta Agonists Revenue in 2022
Figure 27. Long-acting Beta Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 28. Product Picture of COPD
Figure 29. Global COPD Sales YoY Growth (2018-2029) & (K Units)
Figure 30. Product Picture of Asthma
Figure 31. Global Asthma Sales YoY Growth (2018-2029) & (K Units)
Figure 32. Product Picture of Other
Figure 33. Global Other Sales YoY Growth (2018-2029) & (K Units)
Figure 34. Global Long-acting Beta Agonists Sales by Application (2018-2029) & (US$ Million)
Figure 35. Global Long-acting Beta Agonists Sales Market Share by Application in 2022 & 2029
Figure 36. North America Long-acting Beta Agonists Sales Market Share in Volume by Application in 2022
Figure 37. North America Long-acting Beta Agonists Sales Market Share in Value by Application in 2022
Figure 38. Europe Long-acting Beta Agonists Sales Market Share in Volume by Application in 2022
Figure 39. Europe Long-acting Beta Agonists Sales Market Share in Value by Application in 2022
Figure 40. Asia-Pacific Long-acting Beta Agonists Sales Market Share in Volume by Application in 2022
Figure 41. Asia-Pacific Long-acting Beta Agonists Sales Market Share in Value by Application in 2022
Figure 42. Latin America Long-acting Beta Agonists Sales Market Share in Volume by Application in 2022
Figure 43. Latin America Long-acting Beta Agonists Sales Market Share in Value by Application in 2022
Figure 44. Middle East and Africa Long-acting Beta Agonists Sales Market Share in Value by Application in 2022
Figure 45. Key Raw Materials Price
Figure 46. Long-acting Beta Agonists Manufacturing Cost Structure
Figure 47. Long-acting Beta Agonists Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries